regeneron_8k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): April 27, 2011 (April 27, 2011)
     
     
  REGENERON PHARMACEUTICALS, INC.  
  (Exact Name of Registrant as Specified in Charter)  

 
New York       000-19034       13-3444607
(State or other jurisdiction of   (Commission File No.)   (IRS Employer Identification No.)
Incorporation)        

  777 Old Saw Mill River Road, Tarrytown, New York 10591-6707  
  (Address of principal executive offices, including zip code)  

  (914) 347-7000  
  (Registrant's telephone number, including area code)  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
  
 

Item 8.01 Other Events.
 
     On April 27, 2011, Regeneron Pharmaceuticals, Inc. and Bayer HealthCare issued a press release reporting positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients with macular edema due to central retinal vein occlusion. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated by reference into this Item.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits
 
99.1       Press Release Reporting Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion, dated April 27, 2011.
 
 

SIGNATURES
 
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: April 27, 2011 REGENERON PHARMACEUTICALS, INC.
   
   
  By:  /s/ Murray A Goldberg
  Name: Murray A. Goldberg
  Title: Senior Vice President, Finance and
  Administration, Chief Financial Officer, Treasurer,
  and Assistant Secretary

 

Exhibit Index
 
Number       Description
99.1   Press Release Reporting Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion, dated April 27, 2011.